In addition, the present review summarizes the literature pertaining to quercetin as an anticancer agent and provides an assessment of the potential utilization of this natural compound as a complimentary or alternative medicine for preventing and treating cancer.
Diet plays a key role to maintaining healthy life. Many natural products present in our diet, such as flavonoids, can prevent the progression of cancer. Quercetin, a distinctive bioactive flavonoid, is a dietary component that has attracted the attention of dietitians and medicinal chemists due to its numerous health-promoting effects. It is an outstanding antioxidant that has a well-documented role in reducing different human cancers. Quercetin exhibits direct proapoptotic effects on tumor cells and thus can inhibit the progress of numerous human cancers. The anticancer effect of quercetin has been documented in numerous in vitro and in vivo studies that involved several cell lines and animal models. On the other hand, the high toxic effect of quercetin against cancer cells is accompanied with little or no side effects or harm to normal cells. Accordingly, this review presents an overview of recent developments on the use of quercetin against different types of cancer along with mechanisms of action.
In addition, the present review summarizes the literature pertaining to quercetin as an anticancer agent and provides an assessment of the potential utilization of this natural compound as a complimentary or alternative medicine for preventing and treating cancer. (Kanadaswami et al., 2005) .
Quercetin (Figure 1 ), chemically known as 3,3′,4′,5,7-pentahydroxyflavone (C 15 H 10 O 7 ), is a naturally occurring polyphenolic flavonoid that is commonly found in different fruits and vegetables such as capers, lovage, dill, cilantro, onions, apples, and berries as in chokeberries, cranberries, and lingonberries. Perhaps, the most important property of this flavonoid is its antioxidant effect. In addition, quercetin can be useful in cancer prevention (Iacopetta et al., 2017) and is known to have antiallergic, anti-inflammatory, and antiviral activities (Y. Liu et al., 2017) . Most importantly, quercetin impedes the propagation of various types of cancers, such as lung, prostate, liver, breast, colon, and cervical (Y. Liu et al., 2017) ; these anticancer properties are exerted through various mechanisms that involve cellular signaling and the ability to inhibit enzymes responsible for the activation of carcinogens. Quercetin displays anticancer effects based on its binding to cellular receptors and proteins (Murakami, Ashida, & Terao, 2008; Shih, Pickwell, & Quattrochi, 2000) . Furthermore, quercetin has been recently reported to have synergistic effects when combined with chemotherapeutic agents such as cisplatin, which may further improve the outcomes of the traditional chemotherapy (Brito et al., 2015) .
As soon as quercetin is absorbed in the gastrointestinal tract, it gets metabolized by phase II enzymes present in the epithelial cells of the stomach and intestines. The combined metabolites are then further processed in the liver and kidney (Abarikwu, Pant, & Farombi, 2012; Nabavi, Nabavi, Mirzaei, & Moghaddam, 2012) . Mechanistically, the catechol structure (B-ring) is methylated at the 3′ or 4′ hydroxyl sites by catechol-O-methyl transferase to produce isorhamnetin and tamarixetin, respectively. Quercetin metabolites seem to accumulate in tissues shortly after quercetin-rich vegetables are consumed. In vitro studies indicated that quercetin metabolites, originating from enterocytes and the liver, serve as antioxidants by impeding oxidation of low-density lipoprotein cholesterol.
On the other hand, and even with the many technological and pharmaceutical advances over the past two decades, cancer continues to be a global concern (Seyed, Jantan, Bukhari, & Vijayaraghavan, 2016) . Scientists attribute 90-95% of all cancers to lifestyle including obesity, outdoor pollution, alcohol consumption among others, whereas the remaining 5-10% are attributed to defective genes (de Martel et al., 2012) . Cancer treatment methods include surgery, radiotherapy, and anticancer drugs (chemotherapy) in addition to other specialized techniques. For years, humans have used herbs as complementary therapy or dietary agents to treat different types of cancer and to influence cellular signaling (Martin, 2006) . In this regard, natural compounds such as quercetin have been employed as alternative drugs in the treatment of cancer. Based on the above discussion, and owing to the wide range of therapeutic options of quercetin against various types of cancer, this review focusses on the current knowledge on the chemo-preventive and therapeutic ability of this natural flavonoid against different types of cancer, along with its mechanisms of action. For this purpose, recent relevant references have been obtained from different databases such as MEDLINE (PubMed), Google Scholar, ScienceDirect, Scopus, Cochrane, SID, and SciFinder. We hope this review will be a valuable addition to the field and will be a great help for researchers. Listed in Table 1 are the anticancer perspectives of quercetin along with the mechanisms in each type of cancer with a list of pertinent references, whereas shown in Figure 2 is the anticancer role of quercetin. Below are details about documented anticancer activities of quercetin.
| ANTICANCER PERSPECTIVES OF QUERCETIN

| Breast cancer
Recent research revealed that treatment of Michigan Cancer Foundation-7 (MCF-7) breast cancer cells with nano-quercetin enhances apoptosis and mRNA expression levels. In addition, quercetin was found to sensitize MCF-7 cells to doxorubicin (Dox) and reduce cellular NAD(P)H quinone oxidoreductase 1 and multidrug resistant protein 1 gene expression levels (Minaei et al., 2016; Suksiriworapong et al., 2016) . Similarly, treatment of MCF-7 and MDA-MB-231 breast cancer cell lines with quercetin led to apoptosis along with G1 phase arrest and considerably suppressed the expression of Twist, CyclinD1, p21, and phospho p38 mitogen-activated protein kinases (p38MAPKs). It has also effectively controlled the expression of Twist, which induces apoptosis in MCF-7 cells due to p16 and p21. These findings suggest that quercetin induces apoptosis in cancer cells via suppression of Twist through p38MAPK Ranganathan, Halagowder, & Sivasithambaram, 2015) .
Research published by Dhumale and coworkers demonstrated that receptor for advanced glycation end-products (RAGE), which is a multi-ligand member of the immunoglobulin superfamily, plays an important role in maintaining cellular homeostasis. The elevated expression of RAGE and its ligand high-mobility group box proteins-1 (HMGB-1) was found in different types of cancer. In addition, aggregation of RAGE with its HMGB1 stimulates a complicated signaling network for cell viability and avoids apoptosis. Hence, quercetin augments apoptosis in MCF-7 cells by hindering the expression of RAGE and HMGB1; this also results in necrotic insult (Dhumale, Waghela, & Pathak, 2015) . Furthermore, lack of estrogen, progesterone, and epidermal growth factor-2 receptors is the typical indicators of triple negative breast cancer (TNBC). Quercetin can induce the expression of Ecadherin and suppression of vimentin levels in TNBC. It has also shown the potential to regulate these epithelial mesenchymal transition (EMT) markers resulted in a mesenchymal-to-epithelial transition.
In addition, quercetin stimulates antitumor activity of Dox by attenuating the migratory ability of TNBC cells (Srinivasan et al., 2016) .
Recent studies indicated that quercetin can enhance the chemosensitivity of breast cancer cells to Dox via inhibiting cell proliferation and invasion, resulting improvement in cell apoptosis, and modulating expression of phosphatase and tensin homolog and p-Akt (S. Z. Li, Qiao, Zhang, & Li, 2015) . Moreover, quercetin has exhibited the inhibitory effect on MCF-7 and MDA-MB-231 human breast cancer cell lines through multiple mechanisms such as up-regulation of miR146a expression, induction of apoptosis, activation of caspase-3 and mitochondrial-dependent pathways, and down-regulation of the expression of epidermal growth factor receptor (EGFR; Tao, He, & Chen, 2015) . It also lowers the tumor number (Metastasis), tumor volume, down-regulates 31 genes, and up-regulates 9 genes in human breast cancer (Steiner et al., 2014) .
In breast malignancies, epidermal growth factor plays a critical role by propagating cell proliferation, angiogenesis, and metastasis. Silver nanoparticle-based quercetin caused a significant reduction in the expression of various proteins including vimentin, Snail, N-cadherin, Twist, Slug, matrix metalloproteinase-2 (MMP-2), MMP-9, vascular endothelial growth factor receptor 2 (VEGFR2), p-EGFR, protein kinase B (Akt), phosphoinositide 3-kinase (PI3K), and glycogen synthase kinase 3 beta (p-GSK3β) and enhanced E-cadherin protein expression in 7,12-dimethylbenz[a]anthracene-induced mammary carcinoma in Sprague-Dawley rats. It also reduced cell viability and capillary-like tube formation, suppressed tube and new blood vessel Chen, Cao, et al. (2015) , X. Chen, Dong, et al. (2015) , and Q. Chen, Li, et al. (2015) Liver cancer Induces apoptosis Guan, Gao, Xu, et al. (2016) Down-regulates the expression of PI3K, PKC, COX-2, and ROS Enhances the expression of p53 and BAX Maurya and Vinayak (2015) Activates p53-ROS crosstalk and induces epigenetic modifications Bishayee, Khuda-Bukhsh, and Huh (2015) Lung cancer Triggers BCL2/BAX-mediated apoptosis, as well as necrosis and mitotic catastrophe Inhibits the migratory potential of A549 cells Klimaszewska-Wiśniewska et al. (2017) Inhibits aurora B activities Reduces the phosphorylation of histone 3 Xingyu et al. (2016) Enhances expressions of nm23-H1 and tissue inhibitor of metalloproteinase Inhibits the protein expression of MMP-2. GW9662, a PPAR-γ antagonist Chuang et al. (2016) and Warnakulasuriya, Ziaullah, and Rupasinghe (2016) Increases miR-21 expression and causes inhibition of PDCD4 induced by [Cr(VI)] Pratheeshkumar et al. (2017) Prostate cancer
Decreases tumor improvement, down-regulates Ki67, and enhances caspase 7 Down-regulates growth factors such as VEGF and EGF Sharma et al. (2016) , P. Wang, Henning, et al. (2016) , and Y. Wang, Zhang, et al. (2016) Prevents TGF-β-induced expression of vimentin and N-cadherin Decreases TGF-β-induced expression of Twist, Snail, and Slug in prostate cancer-3 cell line Baruah, Khandwekar, and Sharma (2016) (Continues) 
Cancer types Mechanisms References
Bladder cancer Inhibits cell proliferation and colony formation of human bladder cancer cells by inducing DNA damage Oršolić et al. (2016) Gastric cancer Inhibits EBV viral protein expressions, including EBNA-1 and LMP-2 proteins Prompts p53-subordinate apoptosis Induces the expression of p53, Bax, and Puma Cleaves caspase-3 and -9 and Parp J. Lee, Lee, Kim, et al. (2016) and H. H. Lee, Lee, Shin, et al. (2016) Causes mitochondrial apoptotic-dependent growth inhibition via the blockade of PI3K-Akt signaling Activates caspase-3 and -9 Down-regulates the Bcl-2 and up-regulates the Bax and cytochrome c Causes mitochondrial apoptotic-dependent growth inhibition via the blockade of PI3K-Akt signaling Shen et al. (2016) Bone cancer Decreases cyclin D1 expression in SKOV3 and U2OSPt cells Catanzaro, Ragazzi, Vianello, Caparrotta, and Montopoli (2015) Inhibits 143B proliferation and up-regulates the expression of miR-217 X. Zhang, Guo, et al. (2015) , J. Y. Zhang, Lin, et al. (2015) , and X. A. Blood cancer Activates caspase-3, -8, and -9 and promotes leukemic cell apoptosis Reduced expression of the antiapoptotic proteins B-cell, lymphoma (Bcl)-2. Enhances expression of the proapoptotic proteins Bcl-2-interacting mediator of cell death F. Y. Chen, Cao, et al. (2015) , X. Chen, Dong, et al. (2015) , and Q. Chen, Li, et al. (2015) Brain cancer Suppresses COX-2 expression by Hsp27 inhibition and acts as both COX-2 and Hsp27 inhibitor Reduces MMP-2 expression Q. C. Li, Liang, Hu, and Tian (2016) and J. Fan (2016) Santos et al. (2015) Decreases mitochondria and rough endoplasmic reticulum injury Reduces filopodia-like structures on the cell surface Induces necrotic cell death and down-regulates the Bcl-2 mRNAs expression. Enhances mitochondrial mRNAs expression Modulates the mitochondrial pathway and the JAK2/STAT3 signaling Wang et al. (2013) Head and neck cancer
Retards colony growth of HSC-3 cells Suppresses the MMP-2 and MMP-9
Chan, Lien, Lee, and Huang (2016) Causes cells arrest at the G1 phase Induces apoptosis, suppresses the expression of Bax, and activates the expression of Caspase-3 and Bcl-2 Reverses gene-encoded Pglycoprotein-mediated MDR Z. Yuan et al. (2015) Cervical cancer Inhibits antiapoptotic AKT and Bcl-2 expression Increases mitochondrial cytochrome-c level Causes cell cycle arrest at G2/M Bishayee et al. (2013) Induces apoptosis via PI3k/Akt pathways Xiang, Fang, and Wang (2014) Significantly inhibits UBE2S expression Lin et al. (2017) Skin cancer Blocks UVB irradiation-induced COX-2 up-expression and NF-kB activation in Hacat cell line Caddeo et al. (2016) Reduces the tumor size and the cumulative number of papillomas. Decreases the serum levels of glutamate oxalate transaminase, glutamate pyruvate transaminase, alkaline phosphatase, and bilirubin Ali and Dixit (2015) Inhibits PI3K and MAPK signaling Attenuates MEK-ERK signaling and influences PI3K/Akt pathway Rafiq et al. (2015) Eye cancer Decreases dose-dependently the RPE cell proliferation, migration, and secretion of VEGF Inhibits the secretion of VEGF evoked by CoCl2-induced hypoxia R. Chen et al. (2014) Thyroid cancer Lowers the cell proliferation and increases rate of apoptosis by caspase activation Downregulates the levels of Hsp90 Decreases chymotrypsin-like proteasome activity Mutlu Altundağ et al. (2016) and Quagliariello et al. (2016) Ovarian cancer Suppresses ROS-induced injury and increases the expression of endogenous antioxidant enzymes W. Li, Liu, et al. (2014) , N. , X. , and W. Li, Zhao, et al. (2014) (Continues) formation, and impeded tumor growth and metastasis of the breast cancer cells through the EGFR/VEGFR-2 signaling pathway (Balakrishnan et al., 2016; Quagliariello et al., 2016) . Quercetin also causes cell cycle arrest and apoptosis in breast cancer cells via modulating Akt and Bcl-2-associated X protein (Bax) signaling mechanistic pathways (Sarkar et al., 2016) . The administration of quercetin at 15 μM suppressed the breast cancer cell proliferation by inducing apoptosis, assuring cell cycle arrest, and attenuating the tumor growth (Rivera, Castillo-Pichardo, Gerena, & Dharmawardhane, 2016 ).
Balakrishnan and colleagues have recently evaluated the effects of gold nanoparticles-conjugated quercetin (AuNPs-Qu-5) in MCF-7
and MDA-MB-231 breast cancer cell lines. These researchers showed that the administration of AuNPs-Qu-5 inhibits cell proliferation in breast cancer cell lines through induction of apoptosis and suppresses EGFR signaling. In addition, treatment with these nanoparticles upregulated the proapoptotic proteins (Bax, Caspase-3) and down-regulated antiapoptotic protein (Bcl-2). Collectively, these AuNPs-Qu-5 particles could be a potential drug delivery system in breast cancer therapy (Balakrishnan et al., 2017) .
In Seo et al., 2016) . In a similar fashion, quercetin inhibits the activity and expression of P-glycoprotein and causes a significant reduction in Dox resistance in MCF-7/ADR breast cancer cells . In female BALB/c nude mice, it has attenuated tumor growth, oncocyte proliferation, and tumor necrosis. It has also modulated serum VEGF and markedly reserved tumor calcineurin activities.
Additionally, it has down-regulated gene expression of VEGF and reduced protein levels of VEGF (X. Zhao et al., 2016) . Adrenaline and noradrenaline (endogenous catecholamines) are secreted by adrenal gland and sympathetic nervous system on exposure to stress. The adrenergic system plays an important role in stress signaling, where 
| Colon cancer
Diet is an important factor associated with colon cancer. Diets that are low in fiber and high in fat, calories, and red meat and processed meats ability of CT26 cells, and can suppress colorectal lung metastasis in the mouse model, and may be a potent therapeutic agent for the treatment of metastatic colorectal cancer (Kee et al., 2016) . Similarly, an investigation by quercetin, a novel quercetin derivative, triggers G 2 phase arrest in colon cancer cells and suppresses propagation. It also induces autophagic cell death through ERK stimulation (Y. Zhao, Fan, et al., 2017; J. Zhao, Liu, et al., 2017) . Similarly, quercetin at a concentration of 5 μM could markedly suppress the migratory and invasive capacity of Caco-2 cells. In addition, results from this investigation revealed that the expression of E-cadherin protein was increased by quercetin, whereas metastasis-related proteins of MMP-2, MMP-9 expression got decreased by it in a dose-dependent manner.
The anti-toll-like receptor 4 (TLR4) antibody of pyrrolidine dithiocarbamate might influence the inhibition of quercetin on cell migration and invasion and the expression of various proteins such as Ecadherin, MMP-2, MMP-9, NF-κB p65, and TLR4. Moreover, quercetin could lessen the production of different inflammation factors including TNF-α, Cox-2, and interleukin 6 (IL-6). Hence, quercetin might exert its anti-colon cancer activity via the TLR4-and/or NF-κB-mediated signaling pathway (M. Han et al., 2016) . The 1,2-dimethyl hydrazine-induced colon cancer causes nephrotoxicity and further increases the blood urea nitrogen, urea, creatinine, and eventually result in a number of aberrant crypts and foci formation.
The potential protective effect of quercetin on cisplatin-induced nephrotoxicity was assessed through lowing the blood urea nitrogen, urea, and creatine and also reduced the aberrant crypt foci number (Q. C. Li, Liang, et al., 2016; J. Li, Tang, et al., 2016) . Similar results were obtained by Saleem et al. (2015) who found that treatment of mice either with quercetin, sodium gluconate, or with the combination has a positive effect against 1,2-dimethyl hydrazineinduced colon cancer.
In human colon adenocarcinoma cells, quercetin significantly enhanced the expression of the endocannabinoids receptor (CB1-R) and further suppressed PI3K/Akt/mTOR. It also induced JNK/JUN pathways and modified the metabolism of β-catenin, either directly or via activation of CB1-R (Refolo et al., 2015) . These findings were confirmed by other researchers . 
| Pancreatic cancer
Research revealed that quercetin induces apoptosis in tumor necrosis factor-related apoptosis-inducing ligand ( Lee, Lee, Min, et al., 2015) . Similarly, quercetin significantly inhibits proliferation, promotes apoptosis, and induces cell cycle arrest within the G1 phase in pancreatic cancer cells. It can also activate caspase-3, -8, and -9 and reduces the mitochondrial membrane potential and can inhibit the expression level of the δ opioid receptor, whereas isoquercitrin was found to have no effect on the κ and μ opioid receptors. Furthermore, quercetin can inhibit ERK phosphorylation, promote JNK phosphorylation, and significantly inhibit xenograft growth in nude mice (F. Y. Chen, Cao, et al., 2015; X. Chen, Dong, et al., 2015; Q. Chen, Li, et al., 2015) .
On the other hand, research conducted by Appari and coworkers revealed that quercetin significantly inhibits viability, migration, expression of MMP-2 and -9, aldehyde dehydrogenase 1 activity, colony, and spheroid formation and triggers apoptosis in pancreatic duc- Quercetin exerts this cytotoxicity against human pancreatic cancer cells trough endoplasmic reticulum stress-mediated apoptotic signaling including pathway, as well as ROS production and mitochondrial dysfunction (J. H. Lee et al., 2013) . Other researchers found that quercetin exerts its antiproliferative effects in pancreatic cancer cells by inducing apoptosis and attenuating the growth of orthotopically transplanted pancreatic xenografts (Angst et al., 2013) . In MIA PaCa-2 pancreatic adenocarcinoma cells, quercetin at 100 μM inhibits tracer glucose-derived glycogen labeling (Σm), slows down glycogen synthesis, and manages tumor cell proliferation (Harris et al., 2012) .
| Liver cancer
The leading cause of liver cancer is cirrhosis due to either hepatitis B, hepatitis C, or excess alcohol intake (Naghavi, Wang, Lozano, et al., 2015) . Other causes include aflatoxin, nonalcoholic fatty liver disease, and liver flukes. The most common types are hepatocellular carcinoma, which makes up to 80% of cases, and cholangiocarcinoma (NCI, 2016) .
Previous studies demonstrated that treatment with nano-capsulated quercetin restricts all changes in diethyl nitrosamine-mediated development of hepatocarcinogenesis, suggesting that this nano-capsulated natural product may be accepted as a potent therapeutic agent in preventing diethyl nitrosamine-mediated hepatocarcinogenesis (Mandal et al., 2014) . In addition, fatty acid esters of quercetin-3-Oglucoside were found to exhibit significant inhibition of HepG2 cell proliferation. Effect of this novel compound was associated with cell ycle arrest in S-phase and apoptosis. Furthermore, quercetin-3-O-glucoside esters showed significant low toxicity to normal liver cells than sorafenib, a chemotherapy drug used in the treatment of hepatocellular carcinoma (Sudan & Rupasinghe, 2015) . Treatment with quercetin at a dose of 50 mg/kg in mice showed a protective effect on cisplatin-induced DNA damage in normal cells, without interfering with the antitumor efficacy of the combined treatment. These results suggest that quercetin can protect the blood, liver, and kidney cells of mice against HIPEC-induced injury and can increase survival of mice by improving the antitumor adaptive immunity with hyperthermia (Oršolić & Car, 2014) .
Quercetin inhibits the growth of cancer cells, which can be attributed to various mechanisms, such as the induction of cell cycle arrest and/or apoptosis, as well as its antioxidant functions. In this respect, Zhao and coworkers evaluated the activity of quercetin in human liver cancer HepG2 cells. These workers found that quercetin can induce apoptosis in human liver cancer HepG2 cells with overexpression of fatty acid synthase. These results suggest that apoptosis is induced by quercetin via the inhibition of fatty acid synthase. Additionally, findings by these researchers suggest that quercetin may be useful for preventing human liver cancer (P. Zhao et al., 2014) . Furthermore, it was demonstrated by a number of researchers that intake of quercetin seems to play a minor regulatory role, whereas supplement doses may have great effects on gene expression in hepatocytes. Further work is certainly required in handling of quercetin supplements (Waizenegger et al., 2015a cell DNA and reduces histone deacetylases to manage cell proliferation and arrest the cell cycle at the sub-G stage. These nanoparticles induce apoptosis in HepG2 cells by activating p53-ROS crosstalk and by enhancing epigenetic modifications leading to inhibited proliferation and cell cycle arrest (Bishayee et al., 2015) . Protein kinase C is a key regulator of cell growth in mammalian cells and is linked with tumor succession. Quercetin, on the other hand, exhibits antitumor activity both in vitro and in vivo in HepG2 cells. It down-regulates the expression of PI3K, protein kinase C, COX-2, and ROS. Additionally, it enhances the expression of p53 and BAX in HepG2 cells (Maurya & Vinayak, 2015) . One of the shortcomings of quercetin in clinics is its poor solubility. To overcome these disadvantages, Guan and coworkers prepared quercetin (QT) as QT-loaded PLGA-TPGS nanoparticles (QPTN) and evaluated its therapeutic efficacy for liver cancer. Results indicated that QPTN could induce HepG2 cell apoptosis in a dose-dependent manner and that QPTN could suppress tumor growth by 59.07%. These researchers concluded that QPTN could be used as a potential intravenous dosage form for the treatment of liver cancer owing to the enhanced pharmacological effects of quercetin with increased liver targeting (Guan et al., 2016) .
| Lung cancer
Several research papers have dealt with quercetin as a chemotherapeutic agent against lung cancer. An investigation by W. Chen, Wang, Zhuang, Zhang, and Lin (2007) improved gemcitabine-induced cell death, which was linked to increased caspase-3 and caspase-9 activities (J. Lee, Han, et al., 2015 ; W. J. Lee, Hsiao, et al., 2015 ; Y. J. S. H. Lee, Lee, Min, et al., 2015; Y. Liu, Wu, & Zhang, 2015) . pyrene-treated animals, supplementation of curcumin (60 mg/kg body weight) and quercetin (40 mg/kg body weight), separate as well as combined, considerably reduced the protein expression of Bcl-2 and amplified the protein expression of Bax. Supplementation also improved the enzyme activities of caspase 9 and caspase 3 (Nair, Malhotra, & Dhawan, 2015) . In addition, a peer group of investigators (Lam et al., 2012; Youn, Jeong, Jeong, Kim, & Um, 2013) factor, and (f) substantially lifts the levels of tumor silencer mir15a and mir330 (P. Wang, Henning, et al., 2016; Y. Wang, Zhang, Lv, Zhang, & Zhu, 2016) . In castration-resistant prostate cancer cells, quercetin improves the therapeutic effect of Doc in through multiple mechanisms including down-regulation of chemoresistance-related proteins (P. Wang, Henning, et al., 2016; . Additionally, in PC3 and DU145 prostate cancer cell lines, a combined treatment with quercetin and curcumin, two known dietary phytocompounds with described DNMT-inhibitory activity, was much more effective than either of them in both inhibition of DNMT and in triggering apoptosis via mitochondrial depolarization. These two natural compounds have the potential for use as chemopreventive agents of androgen resistance in prostate cancer . Yang, Liu, Liao, et al., 2015; F. Yang, Song, et al., 2015) .
In LAPC-4-AI and PC-3 prostate cancer cells, quercetin at a concentration of 5 μM significantly enhanced cell cycle arrest at G2/M phase and increased apoptosis. Quercetin also increased the inhibition of PI3K/Akt and the STAT3 signaling pathways compared with Doc alone and decreased the protein expression of multidrug resistancerelated protein (Y. Wang, Han, et al., 2015; P. Wang, Henning, Heber, & Vadgama, 2015; P. Wang, Phan, et al., 2015; J. Wang, Zhang, Cheng, Zhang, & Li, 2015) . Y. Wang, Han, et al. (2015) , P. , P. Wang, Phan, et al. (2015) and J. Wang, Zhang, et al. (2015) evaluated the effect of a combination of arctigenin and quercetin, two promising natural chemo-preventive agents, on Androgendependent LAPC-4 and LNCaP prostate cancer cells. Results from this investigation revealed that the combination of the aforementioned compounds inhibits both androgen receptor and PI3K/Akt pathways.
In addition, results showed that the mixture inhibitions cell migration in both cell lines compared with individual compounds tested (Y. Wang, Han, et al., 2015; P. Wang, Phan, et al., 2015; J. Wang, Zhang, et al., 2015) . In androgen-dependent LNCaP and androgen-independent PC-3 human prostate cancer cell lines of male BALB/c nude, the inhibitory effect of a combination of quercetin and 2-methoxyestradiol was investigated. Results
showed that the combination appreciably inhibits prostate cancer xenograft tumor growth for both cell lines as compared with control, which suggests that the combination can serve as a novel clinical treatment regimen for prostate cancer (F. Q. Yang, Liu, Li, et al., 2015; Z. Yang, Liu, Liao, et al., 2015; F. Yang, Song, et al., 2015) . and Parp at comparative levels (J. Lee, Lee, Kim, et al., 2016; H. H. Lee, Lee, Shin, et al., 2016) . In gastric cancer stem cells, quercetin In human gastric carcinoma, the EPG85-257P cell line and its daunorubicin-resistant variation EPG85-257RDB, quercetin exerted antiproliferative impact (with an IC 50 value of 12 μM after 72 hr), predominantly through induction of apoptosis, abatement of P-glycoprotein expression, hindrance of medication transport, and down-regulation of ABCB1 gene expression (Borska et al., 2012) . Similarly, quercetin could inhibit the proliferation of human gastric cancer by down-regulation of the expressions of leptin and leptin receptor protein, leptin mRNA, and leptin receptor mRNA through the JAK-STAT pathway in MGC-803 cells (Qin et al., 2012) .
| Gastric or stomach cancer
In an effort to identify an effective drug as a potential candidate for 
| Bone cancer
Osteosarcoma is becoming the most common malignant bone tumor in children and young adults. The main difficulties in osteosarcoma treatment are the occurrence of metastases, severe side effects, and chemoresistance. Treatment of human osteosarcoma cell line 143B with quercetin substantially caused growth inhibition, G2/M phase arrest, and prompted apoptosis (Berndt et al., 2013) . Quercetin blocked the extension of human methotrexate safe osteosarcoma cell U-2OS/MTX300 in a dose and time-dependent route through inciting cell apoptosis, cutting down mitochondrial layer potential, releasing of mitochondrial cytochrome c to cytosol, and dephosphorylating of Akt (Yin et al., 2012) . Similarly, the examination disclosures of Sekeroğlu and Sekeroğlu (2012) Lee, Lee, Min, et al., 2015) .
In human K562 chronic myeloid leukemia cells, treatment with quercetin considerably reduced both the proportion of apoptotic cells and caspase-3 activity. It also altered the cell cycle profile, particularly after 48 hr of exposure. In addition, it increased the Bcl-2 protein expression and stopped quercetin-induced down-regulation of Mcl-1 and Bcl-xL (Brisdelli et al., 2014) . Interestingly, the combination quercetin and menadione (vitamin K3) can improve the outcome of conventional leukemia therapies mediated by opening of the mitochondrial permeability transition pore (Baran et al., 2014) . In EBV-negative Burkitt's lymphoma cells, quercetin reduced c-Myc expression and inhibited the PI3K/AKT/mTOR activity. It additionally induced absolute autophagy flux in Burkitt's lymphoma cells that contributes to c-Myc reduction in some of these cells (Granato et al., 2016) .
The effects of quercetin on Hedgehog signaling in chronic myeloid leukemia KBM7 cells were recently examined by Li and coworkers. These workers showed that quercetin significantly inhibits KBM7 cell proliferation, induces cell apoptosis, and blocks cell cycle at G1 phase, in dose-dependent manners. It can also increase p53 and Caspase-3 expression (W. Li, Liu, et al., 2014; N. Li, Sun, et al., 2014;  X. W. Li, Zhao, et al., 2014) . In a diffuse large B-cell lymphoma cell line, quercetin synergistically improved rituximab-induced growth inhibition and apoptosis. It additionally, exerted inhibitory activity against STAT3 pathway and down-regulated the expression of survival genes (W. Li, Liu, et al., 2014; N. Li, Sun, et al., 2014; X. Li, Wang, et al., 2014; W. Li, Zhao, et al., 2014) . In human myeloma cell lines U266, KM3 and RPMI8226, and malignant meso- 
| Brain cancer
Chae and coworkers evaluated the apoptotic effect of quercetin on human malignant pleural mesothelioma. Quercetin at 20-80 μM concentrations considerably reduced the mesothelioma cell viability and induced apoptotic cell death in human malignant pleural mesothelioma (MSTO-211H). It additionally enhanced the sub-G₁ cell population, and was found to interact with Sp1, and considerably inhibited its expression at the protein and mRNA levels. Quercetin also reduced the levels of Sp1 regulatory genes, such as cyclin D1, Mcl-1, and survivin. Interestingly, apoptotic signaling cascades are activated via the cleavage of Bid, caspase-3, and PARP, and by the down-regulation of Bcl-xL and the up-regulation of Bax. These results strongly suggest that Sp1 might be a novel molecular target of quercetin in human malignant pleural mesothelioma (Chae et al., 2012) . In U87 glioma cells 
| Head and neck cancer
These cancers are more common among men than they are among women and are diagnosed more often among people over age 50 than they are among younger people. Treatment for head and neck cancer can include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of treatments (American Cancer Society, 2017a , 2017b . Quercetin in SAS human oral cancer cells has an anticancer role by inhibiting the expression and activity of MMP-2 and MMP-9 and reducing the protein levels of MMP-2, -7, -9, and -10, VEGF, and NF-κB p65. It can also reduce inducible nitric oxide synthase, COX-2, urokinase-type plasminogen activator, PI3K, IKBα, IKB-α/β, phosphorylated nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor kinase, alpha/beta (p-IKKα/β), focal adhesion kinase, son of sevenless homolog-1, growth factor receptorbound protein-2, mitogen-activated protein kinase kinase kinase-3, mitogen-activated protein kinase kinase kinase-7, ERK1/2, p-ERK1/ 2, JNK1/2, p38, p-p38, Jun proto-oncogene (c-JUN), and p-c-JUN (Lai et al., 2013) . In EGFR-overexpressing HSC-3 and TW206 oral cell cycle arrest and apoptosis and blocks invasion and angiogenesis (Priyadarsini, Vinothini, Murugan, Manikandan, & Nagini, 2011) .
In numerous oral cancer cell lines (SCC-1483, SCC-25, and SCC-QLL1), administration of quercetin at a concentration of 40 μM significantly induced apoptosis and exhibited cleavage of PARP. Furthermore, Caspase-3 activity assay revealed that induction of apoptosis by quercetin was caspase-3-dependent (Kang et al., 2010) . Similarly, 
| Cervical cancer
Cervical cancers are some of the principal causes of cancer-related death among women in developing countries (Ojesina et al., 2014) .
Surgery is still the first choice of cervical cancer treatments; however, chemotherapy has been widely suggested to avoid recurrence in postoperative management of cervical cancers (S. Y. Liu & Zheng, 2013) .
Due to drug resistance and sever toxicities, there is a need to explore more reliable and less toxic therapeutic approaches to treat cervical cancers. Quercetin proved to be a multipurpose anticancer molecule.
In (Xiang et al., 2014) . In a similar fashion, Wang and coworkers employed MTT, flow cytometry, and MDC staining to evaluate proliferation, apoptosis, and autophagy, respectively, after treatment with quercetin in HeLa cells.
In addition, they used western blot assay to detect LC3-I/II, Beclin 1, active caspase-3, and S6K1 phosphorylation. Results revealed that quercetin can inhibit HeLa cell production and initiate protective autophagy at low concentrations (P. Wang, Henning, et al., 2016; . In human cervical carcinoma HeLa cells, quercetin caused introduction of apoptosis and remained efficient for extended period of time (48 hr), decreased Hsp27 and Hsp72 expression, and raised caspases actions (Bądziul, Jakubowicz-Gil, Paduch, Głowniak, & Gawron, 2014; Luo et al., 2016) . from 37% to 83% and increased rate of cell apoptosis from 18.71% ± 2.61% to 70.00% ± 4.05% (W. 
| Thyroid cancer
Radioactive iodine (best known as 
| Ovarian cancer
Ovarian cancer, one of the most common female malignancies, accounts for the leading death rate among the gynecologic cancers.
Risk factors include age, null parity, early menarche, late menopause, and family history, whereas pregnancy and breastfeeding decrease this risk (Gao et al., 2012 ).
In the quest to develop drugs for cancer chemotherapy, Nessa and colleagues examined the use of combination of drugs acting synergistically to overcome drug resistance. In their study, two known anticancer phytochemicals, quercetin and thymoquinone, were combined with two platinum drugs, cisplatin and oxaliplatin, which are commonly used to treat different types of cancer, including ovarian cancer. This combination was tried against two human epithelial ovarian cancer cell lines, A2780 and its cisplatin-resistant form A2780.
Results revealed that the greatest synergism is achieved when the phytochemical is added first followed by platinum drug 2 hr later, and the least synergism is observed when the two compounds were administered as a bolus. It was then suggested that addition of the phytochemical 2 hr before platinum drug may sensitize cancer cells to platinum action, thus offering a means to overcome drug resistance (Nessa, Beale, Chan, Yu, & Huq, 2011) . Similarly, researchers encapsulated quercetin into biodegradable monomethoxy poly(ethylene gly- In human ovarian cancer C13* and SKOV3 cells, quercetin at concentrations of 40-100 μM displayed proapoptotic effect. In addition, it suppressed ROS-induced injury, reduced intracellular ROS level, and improved the expression of endogenous antioxidant enzymes.
These results suggest an ROS-mediated mechanism of reducing antineoplastic drugs. Furthermore, quercetin triggered a considerable reduction of therapeutic efficiency of cisplatin and ROS-induced damage in xenograft tumor tissue (W. Li, Liu, et al., 2014; N. Li, Sun, et al., 2014; X. Li, Wang, et al., 2014; W. Li, Zhao, et al., 2014) . Similarly, quercetin repressed the proliferation of SKOV-3 cells in a time-and dose-dependent approach, prompted cell apoptosis, and initiated ovarian cancer SKOV-3 cell cycle arrest in the G 0 /G 1 phase and a substantial reduction in the percentage of cells at the G 2 /M phase (Arzuman, Beale, Yu, & Huq, 2015; Ren, Deng, Ai, Yuan, & Song, 2015) . Additionally, treatment of SKOV-3 and OVCAR-8 ovarian cancer cells with quercetin induced apoptosis, activated caspase-3 and increased sensitivity to cisplatin, and reduced expression and activation of EGFR.
In addition, quercetin deactivated MAPK-ERK pathway; induced down-regulation of cyclin D1, DNA-PK, phospho-histone H3, and up-regulation of p21; and arrested cell cycle development (Y. Wang, Han, et al., 2015; P. Wang, Phan, et al., 2015; J. Wang, Zhang, et al., 2015) . Similarly, quercetin significantly improved the expression levels of cleaved caspase-3 and prompted overexpression of miR-145 in SKOV-3 and A2780 ovarian cancer cells (Zhou, Gong, Ding, & Chen, 2015) . Furthermore, in ovarian cancer, pretreatment with quercetin considerably increased cisplatin cytotoxicity and activated the three branches of endoplasmic reticulum stress. It additionally suppressed STAT3 phosphorylation, leading to down-regulation of the BCL-2 gene downstream of STAT3, and improved the antitumor effect of cisplatin in a xenograft mouse model of ovarian cancer (Arzuman, Beale, Chan, Yu, & Huq, 2014; F. Q. Yang, Liu, Li, et al., 2015; Z. Yang, Liu, Liao, et al., 2015; F. Yang, Song, et al., 2015) . Finally, a review pertaining to quercetin and ovarian cancer has been recently published (Parvaresh et al., 2016) .
| Kidney cancer
Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. Factors that increase the risk of kidney cancer include smoking, which can double the risk of the disease, regular use of nonsteroidal anti-inflammatory drugs such as ibuprofen and naproxen, obesity, faulty genes, a family history of kidney cancer, having kidney disease that needs dialysis, being infected with hepatitis C, and previous treatment for testicular cancer or cervical cancer (Lipworth, Tarone, & McLaughlin, 2006) . induced caspase-3 cleavage (twofold), increased PARP cleavage, and reduced the expression of specificity protein Sp1, Sp3, and Sp4 mRNA (W. Li, Liu, et al., 2014; N. Li, Sun, et al., 2014; X. Li, Wang, et al., 2014;  W. Li, Zhao, et al., 2014) .
| Mesothelioma cancer
In proteins, and (c) the appearance of a sub-G0/G1 peak in the flow cytometric assay. These findings highlight the importance of Nrf2 in cytoprotection, survival, and drug resistance, in addition to the potential significance of targeting Nrf2 as a promising strategy for overcoming resistance to chemotherapeutics in MM (J. Lee, Han, et al., 2015;  W. J. Lee, Hsiao, et al., 2015; S. H. Lee, Lee, Min, et al., 2015) .
| CONCLUSIONS
Diet in combination with chemotherapeutics agents has been gaining popularity in the fight against diseases such as cardiovascular disorders, cancer insurgence, and immune dysfunction. In addition, utilization of conventional therapies such as natural products, particularly in treating cancer, has attracted the attention of the scientific and medical communities due to their lesser side effects and cost. Quercetin, a flavonoid antioxidant found in plant foods, such as leafy greens, tomatoes, berries, broccoli, onions, and apples, is considered as one of the most abundant antioxidants in the human diet and plays an important role in fighting free radical damage, the effects of aging, and inflammation. Its wide accessibility, efficacy, and a broad range of activity, and low toxicity as compared with other examined compounds, make it an attractive chemical in the fight against diseases including cancer. It has been recognized and employed as an alternative drug in treating different cancers alone or in combination with other chemotherapeutic drugs. Certainly, a variety of evidences have been presented in its favor in combatting cancer; however, some reports demand that further scientific research is needed. In this review, we have shown that quercetin provides a wide range of preventive and therapeutic options against different types of cancer, along with a description of the various mechanisms by which this compound exerts its action. In summary, this review reveals that quercetin can be an important complementary medicine for the prevention and treatment of different types of cancers, owing to its natural origin, safety, and low cost relative to synthetic cancer drugs. However, further studies are needed on this natural compound. Furthermore, because most of the findings cited in the current review are based on in vitro and in vivo studies, which do not necessarily represent the effect of quercetin in human, more investigations that involve different pharmacokinetic parameter are recommended in the future before this substance hits the market as a prescribed drug. Moreover, development of standardized extract or dosage could also be pursued in clinical trials.
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